Short Interest in Frazier Lifesciences Acquisition Co. (NASDAQ:FLAC) Drops By 88.0%

Frazier Lifesciences Acquisition Co. (NASDAQ:FLAC) saw a significant decrease in short interest in August. As of August 31st, there was short interest totalling 2,000 shares, a decrease of 88.0% from the August 15th total of 16,700 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 14,000 shares, the short-interest ratio is presently 0.1 days.

Several institutional investors have recently modified their holdings of FLAC. CNH Partners LLC bought a new stake in Frazier Lifesciences Acquisition during the first quarter valued at $249,000. Schonfeld Strategic Advisors LLC bought a new stake in Frazier Lifesciences Acquisition during the first quarter valued at $104,000. Periscope Capital Inc. bought a new stake in Frazier Lifesciences Acquisition during the first quarter valued at $1,432,000. Vivaldi Asset Management LLC bought a new stake in Frazier Lifesciences Acquisition during the first quarter valued at $473,000. Finally, Alyeska Investment Group L.P. bought a new stake in Frazier Lifesciences Acquisition during the first quarter valued at $7,121,000. 36.70% of the stock is currently owned by institutional investors.

Shares of NASDAQ:FLAC opened at $9.85 on Wednesday. The company has a fifty day moving average of $9.74 and a 200-day moving average of $9.84. Frazier Lifesciences Acquisition has a 52-week low of $9.56 and a 52-week high of $12.39.

About Frazier Lifesciences Acquisition

Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.

Further Reading: S&P/ASX 200 Index

Receive News & Ratings for Frazier Lifesciences Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frazier Lifesciences Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.